Research programme: anti-cancer therapeutics - Aurigene/Curis

Drug Profile

Research programme: anti-cancer therapeutics - Aurigene/Curis

Alternative Names: AUPM-170; AUPM-327; CA 327; PD-L1 antagonists - Aurigene/Curis; PD-L1/TIM-3 antagonists - Aurigene/Curis; PD-L1/VISTA antagonists - Aurigene/Curis; Programmed death ligand-1 antagonists - Aurigene/Curis

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Small molecules
  • Mechanism of Action CD274 antigen inhibitors; HAVCR2 protein inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Oct 2016 Curis exercises its option to exclusively license small molecule antagonists of programmed death ligand-1 (PD-L1) and T-cell immunoglobulin and mucin domain containing protein-3 (CA 327)
  • 11 Oct 2016 Aurigene announces intention to submit IND for CA 327 in 2017
  • 21 Jan 2015 Small molecule antagonists for immuno-oncology and precision oncology targets licensed to Curis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top